EA
FATE icon

Emerald Acquisition’s Fate Therapeutics FATE Stock Holding History

Emerald Acquisition’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$67K Sell
21,550
-59,054
-73% -$143K ﹤0.01% 2867
2016
Q2 		$137K Buy
+80,604
New +$146K ﹤0.01% 2788

Other funds holding FATE

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return

Emerald Acquisition's FATE Position: Q3 2016 in Review

Emerald Acquisition reduced its Fate Therapeutics (FATE) stake by 73% in Q3 2016, selling an estimated $143K and leaving 21,550 shares worth $67K. The position accounts for ﹤0.01% of the portfolio, ranked #2867.

Emerald Acquisition first reported a position in FATE in Q2 2016 and has held it in 2 quarters since. The position peaked at $137K in Q2 2016. 40 funds tracked by Wall St. Rank hold FATE as of Q3 2016.

  • Emerald Acquisition held 21,550 shares of Fate Therapeutics worth $67K as of Q3 2016.
  • Emerald Acquisition sold 59,054 Fate Therapeutics shares in Q3 2016, an estimated $143K.
  • Fate Therapeutics made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2867 holding.
  • Emerald Acquisition first reported a position in Fate Therapeutics in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Fate Therapeutics position peaked at $137K in Q2 2016.
  • 40 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.